A2F ASSOCIATES LIMITED

Their core work

A2F Associates is a UK-based SME that provides specialized support services to translational medicine and clinical-stage research projects, with a strong focus on health and biomedical sciences. Their consistent participation across gene therapy, regenerative medicine, and metabolic disease projects suggests they contribute project management, regulatory affairs, or clinical development expertise to large health research consortia. They help academic and clinical teams navigate the path from laboratory discoveries to clinical trials, particularly in cardiovascular and rare disease therapeutics.

What they specialise in

How they've shifted over time

In the early phase (2015-2016), A2F Associates worked across diverse therapeutic areas — liver disease (CARBALIVE), diabetes systems biology (T2DSystems), and rare bone disorders (BOOSTB4) — suggesting a generalist support role in health research. From 2017 onward, their focus narrowed significantly toward cardiovascular gene therapy, with both ReGenHeart and CardioReGenix centering on heart disease treatment through genetic and regenerative approaches. Their largest single funding allocation (EUR 718K for CardioReGenix in 2019) confirms this strategic shift toward advanced therapeutics for cardiovascular conditions.

A2F Associates is deepening its commitment to cardiovascular gene therapy, making them a relevant partner for anyone developing next-generation cardiac treatments heading into clinical stages.

How they like to work

A2F Associates operates exclusively as a consortium participant — they have never coordinated a project, which is typical for specialist SMEs that contribute specific expertise rather than leading large research programmes. With 57 unique partners across 14 countries from just 5 projects, they integrate into large, internationally diverse consortia (averaging 11+ partners per project). This broad network with no repeated coordination role suggests they are a trusted specialist brought in by different lead institutions for their specific capabilities.

A2F Associates has built a broad European network of 57 unique partners across 14 countries through 5 health research projects. Their connections span major EU research nations, reflecting the large consortium sizes typical of Horizon 2020 health RIA projects.

What sets them apart

A2F Associates occupies a niche as a UK-based private SME embedded in high-profile translational health research consortia — a relatively uncommon profile since most SMEs in health projects are either biotech firms or IT providers. Their progression from broad health topics to focused cardiovascular gene therapy signals genuine domain deepening rather than opportunistic project-hopping. For consortium builders, they offer an experienced partner who understands clinical-stage research logistics and has a track record of working within large, multi-country teams.

Highlights from their portfolio

• CardioReGenix
  Their largest project by far (EUR 718K funding), representing a strategic commitment to next-generation cardiovascular gene therapies using ncRNA approaches.
• BOOSTB4
  An ambitious prenatal stem cell therapy project for osteogenesis imperfecta — one of few H2020 projects targeting rare bone diseases before birth.
• T2DSystems
  A comprehensive systems biomedicine project integrating genomics, epigenomics, and metabolomics data for type 2 diabetes — showcasing multi-omics analytical breadth.